Company intelligence / Profile preview

ProSkelia

Romainville, France

Ownership: Private
Development stage: Other

Overview

ProSkelia was a French biotechnology company focused on the discovery and development of small molecule therapeutics for bone and joint diseases. Spun off from Aventis in 2002, the company inherited a robust portfolio of research programs targeting metabolic bone disorders such as osteoporosis and bone metastasis. In 2004, ProSkelia merged with the Scottish pharmaceutical company Strakan to form ProStrakan, creating a significant international specialty pharma entity. The company's lead programs included hormonal therapies and selective estrogen receptor modulators designed to regulate bone density and health.

Therapeutic areas: OncologyEndocrinologyRheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Aventis

Beyond the preview

Go deeper on ProSkelia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProSkelia.

Explore the full profile